CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02675946 |
|
Recruitment Status : Unknown
Verified January 2022 by Curegenix Inc..
Recruitment status was: Recruiting
First Posted : February 5, 2016
Last Update Posted : January 26, 2022
|
Sponsor:
Curegenix Inc.
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Curegenix Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | March 2023 |
| Estimated Study Completion Date : | March 2023 |